Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis

Simple item page
AuthorMohammad Ali Maparen
AuthorMohammad Omidianen
Authoren
Issued Date2010-04-30en
AbstractIntroduction and objective: Oral metronidazole is reported before as effective treatment of cutaneous leishmaniasis. The aim of the present study was to evaluate the efficacy of intralesional metronidazole injection versus intralesional meglumine antimoniate (Glucantim®) in the treatment of cutaneous leishmaniasis. Materials and methods: The 36 patients with clinical and parasitologic diagnosis of cutaneous leishmaniasis participated in this study. The patients were randomly divided into two groups. Group one, 18 patients were treated with weekly intralesional of Glucantim injections, and group two, 18 patients were treated with weekly intralesional injections of metronidazole. Intralesional injections was administered enough to blanch the lesions surfaces (0.5-2ml for each lesion in both groups). Results: Twenty eight patients completed the study. Sixteen patients in group one and 12 patients in group two. In group one, 13 patients recovered with eight injections (81%). and of group two, only three patients recovered with eight injections (16.6%). The pain of intralesional injections of metronidazole was much more than the Glucantim injections. Conclusions: Intralesional metronidazole injections have little effect for the treatment of cutaneous leishmaniasis.en
DOIhttps://doi.org/en
KeywordCutaneous leishmaniasisen
KeywordMeglumine antimoniateen
KeywordGlucantimen
KeywordMetronidazoleen
PublisherBrieflandsen
TitleIntralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasisen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
74430-pdf.pdf
Size:
91.54 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Jundishapur Journal of Microbiology